Compare · STEM vs TMO
STEM vs TMO
Side-by-side comparison of Stem Inc. (STEM) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- STEM operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $250.83B, about 6681.0x STEM ($37.5M).
- Over the past year, STEM is down 72.7% and TMO is up 46.0% - TMO leads by 118.7 points.
- TMO has been more active in the news (3 items in the past 4 weeks vs 1 for STEM).
- Both have 25 recent analyst ratings on file.
- Company
- Stem Inc.
- Thermo Fisher Scientific Inc
- Price
- $4.68+3.77%
- $674.51-0.02%
- Market cap
- $37.5M
- $250.83B
- 1M return
- -17.75%
- +6.96%
- 1Y return
- -72.68%
- +45.99%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 1992
- News (4w)
- 1
- 3
- Recent ratings
- 25
- 25
Stem Inc.
Stem, Inc. provides artificial intelligence (AI)-driven clean energy storage services. It delivers and operates smart battery storage solutions that maximize renewable energy generation and help build a resilient grid. The company's Athena, a AI-powered analytics platform software that uses artificial intelligence and machine learning to automatically switch between battery power, onsite generation, and grid power. Athena stabilizes the grid, reduces carbon emissions, and solves renewable intermittency across the network of distributed energy storage systems. The company serves customers, including Fortune 500 corporate energy users, project developers and installers, and utilities and independent power producers. Stem, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest STEM
- Stem upgraded by UBS with a new price target
- SEC Form S-8 filed by Stem Inc.
- SEC Form 10-Q filed by Stem Inc.
- Stem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Stem Announces Second Quarter 2026 Results
- Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary
- Director Shivram Krishna converted options into 7,486 shares, increasing direct ownership by 241% to 10,597 units (SEC Form 4)
- Director Buzby David S converted options into 7,486 shares (SEC Form 4)
- Director Daley Adam converted options into 7,486 shares, increasing direct ownership by 62% to 19,535 units (SEC Form 4)
- Director Tammineedi Anil converted options into 7,486 shares, increasing direct ownership by 94% to 15,473 units (SEC Form 4)
Latest TMO
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)